Effect of Antiretroviral Therapy and Hepatitis C Co-infection on Changes in Lipid Levels in HIV-Infected Patients 48 Weeks After Initiation of Therapy

REFERENCES

• Stapleton JT. Hepatic and pancreatic diseases in HIV infec-tion. In: Singh N, Shafer RW, Swindells S, eds. Approach Towards Management of Human Immunodeficiency Virus Infection and Its Related Complications. Pittsburgh: ESUN Technologies; 2003.
   Google Scholar
• Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Int Med. 2003;138:197–207.
   PubMed Web of Science ®Google Scholar
• Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of Type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–599.
   PubMed Web of Science ®Google Scholar
• Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut. 2005;54: 903–906.
   Google Scholar
• Taiwo BO. Insulin resistance, HIV infection, and anti-HIV therapies. AIDS Reader 2005;15:171–176.
   PubMedGoogle Scholar
• Polgreen PM, Fultz SL, Justice AC, et al. Association of hypocholesterolemia with hepatitis C virus infection in HIV-infected people. HIV Med. 2004;5:144–150.
   PubMed Web of Science ®Google Scholar
• Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the vis-ceral fat area in nonobese and nondiabetic patients. J Viral Hepat. 2007;14:600–607.
   PubMed Web of Science ®Google Scholar
• Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care. 2005;19:356–365.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis. 2003;16: 19–23.
   PubMed Web of Science ®Google Scholar
• Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommen-dations from the HIV-HCV International Panel. AIDS. 2002; 16:813–828.
   PubMed Web of Science ®Google Scholar
• Dube MP. Disorders of glucose metabolism in patients in-fected with human immunodeficiency virus. Clin Infect Dis. 2000;31:1467–1475.
   PubMed Web of Science ®Google Scholar
• Giral P, Serfaty L, Andreani T, et al. Hypocholestrolemia is associated to chronic hepatitis C [abstract 702]. Hepatol-ogy. 1993;18:232.
   Web of Science ®Google Scholar
• Maggi G, Bottelli D, Gola D, et al. Serum cholesterol and chronic hepatitis C. hal J GastroenteroL 1996;28:436–440.
   Web of Science ®Google Scholar
• Zoli M, Cordianai MR, Marchesini G, et al. Prognostic in-dicators in compensated cirrhosis. Am J Gastroenterol. 199186: 1508–1513.
   Google Scholar
• D'Arienzo A, Manguso F, Scaglione G, et al. Prognostic value of progressive decrease in serum cholesterol in pre-dicting survival in Child-Pugh C viral cirrhosis. Scand J GastroenteroL 1998;33:1213–1218.
   PubMed Web of Science ®Google Scholar
• Stapleton JT, Swindells S, Polgreen P. Hepatitis C virus infection is associated with a decreased risk of hyper cho-lesterolemia but not hyperglycemia in HIV-infected people. In: Program and abstracts of the International AIDS Confer-ence; 2002; Barcelona. Abstract number MoOrB113.
   Google Scholar
• Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS. 2007;21:71–76.
   Google Scholar
• Torti C, Patroni A, Tinelli C, et al. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after hightly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:315–317.
   PubMed Web of Science ®Google Scholar
• Patroni A, Torti C, Tomasoni L, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials. 2002;3:451–461.
   PubMedGoogle Scholar
• Fabris C, Federico E, Soardo G, et al. Blood lipids of pa-tients with chronic hepatitis: differences related to viral etiology. Clinic Chimica Acta. 1997;261:159–165.
   PubMed Web of Science ®Google Scholar
• Collazos J, Mayo J, lbarra S, et al. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS. 2003;17:927–929.
   PubMed Web of Science ®Google Scholar
• Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005;55:800–804.
   PubMed Web of Science ®Google Scholar
• Villano SA, Vlahov D, Nelson KE, et al. Incidence and risk factors for hepatitis C among injection drug users in Balti-more, Maryland. J Clin MicrobioL 1997;35:3274–3277.
   PubMed Web of Science ®Google Scholar
• George SL, Gebhardt J, Klinzman D, et al. Hepatitis C virus (HCV) viremia in HIV-infected individuals with nega-tive HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31:154–162.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acouir Immune Defic Syndr 2001;26: 340–344.
   PubMed Web of Science ®Google Scholar
• Chamie G, Bonacini M, Bangsberg DR, et al. Factors asso-ciated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis. 2007;44:577–583.
   PubMed Web of Science ®Google Scholar
• Xiang J, Klinzman D, McLinden J, et al. Characterization of hepatitis G virus (GB-C virus) particles: Evidence for a nucleocapsid and expression of sequences upstream of the El protein. J Virol. 1998;72:2738–2744.
   PubMed Web of Science ®Google Scholar
• Prince AM, Huima-Byron T, Parker TS, et al. Visualization of hepatitis C virions and putative defective interfering par-ticles isolated from low-density lipoproteins. J Viral Hepat. 1996;3:11–17.
   PubMed Web of Science ®Google Scholar
• Thomssen R, Bonk S, Propfe C, et al. Association of hepa-titis C virus in human sera with beta-lipoproteins. Med Microbiol ImmunoL 1992;181:293–300.
   PubMed Web of Science ®Google Scholar
• Monazahian M, Kippenberger S, Mueller A, et al. Binding of human lipoproteins (low, very low, high density lipo-proteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol ImmunoL 2000;188:177–184.
   PubMed Web of Science ®Google Scholar
• Wunschmann S, Muller HM, Stipp CS, et al. In vitro interac-tion between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cel-lular binding of both HCV E2 and LPs. J Infect Dis. 2006; 194:1058–1067.
   PubMed Web of Science ®Google Scholar
• Wunschmann S, Klinzman D, Medh J, et al. Characteriza-tion of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low density lipoprotein receptor. J Virol. 2000;74:10055–10062.
   PubMed Web of Science ®Google Scholar
• Andre P, Komurian-Pradel F, Deforges S, et al. Character-ization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol. 2002;76:6919–6928.
   PubMed Web of Science ®Google Scholar
• Monazahian M, Bohme I, Bonk S, et al. Low density lipo-protein receptor as a candidate receptor for hepatitis C virus. J Med Virol. 1999;57:223–229.
   PubMed Web of Science ®Google Scholar
• Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other Flaviviridae viruses enter cells via low density li-poprotein receptor. Proc Natl Acad Sci USA. 1999;96: 12766–12771.
   PubMed Web of Science ®Google Scholar
• Hope RG, Murphy DJ, McLauchlan J. The domains re-quired to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. J Biol Chem. 2002;277:4261–4270.
   Google Scholar
• Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human im-munodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis. 2002; 34:831–837.
   PubMed Web of Science ®Google Scholar